Adenosine, an intermediate product in the metabolism of ATP, is thought to produce vasodilatation in all vascular beds with the exception of the kidney. Due to its theoretical potential as a pulmonary vasodilator, we studied the hemodynamic effects of adenosine in the pulmonary vasculature of chronically instrumented awake sheep. Adenosine produced significant pulmonary vasoconstriction instead of the expected vasodilatation. Bolus injections of adenosine into the superior vena cava produced a dose-dependent increase in pulmonary artery pressure that was entirely due to an increase in vascular resistance, since cardiac output decreased slightly. This effect is produced via activation of specific cell surface adenosine receptors, since it was blocked by the adenosine-receptor antagonists theophylline and dipropylsulfophenylxanthine. The cell type involved in adenosine-induced pulmonary vasoconstriction appears to be located within the lung, since vasoconstriction was blunted when adenosine was infused into the left atrium, distal to the lung. However, adenosine does not directly vasoconstrict the pulmonary vasculature, because its effect could be completely abolished by cyclooxygenase inhibition with either indomethacin or ibuprofen and by a thromboxane A 2 /prostaglandin endoperoxide-receptor antagonist (SQ 29,548). Adenosineinduced vasoconstriction was also greatly reduced after inhibition of thromboxane synthesis. Thus, adenosine produced pulmonary vasoconstriction through generation of a thromboxane/ endoperoxide product. Whether endogenous adenosine is involved in the generation of pulmonary vasoconstriction seen in pathophysiological states remains to be determined. To our knowledge, this is the first clear evidence for adenosine-induced vasoconstriction outside the kidney and for an interaction between adenosine and eicosanoid mechanisms. (Circulation Research 1989;65:1516-1525 A denosine is a vasodilator in virtually all vascular beds with the exception of the kidney. A product of ATP metabolism, adenosine has been postulated to be an endogenous modulator of blood flow. Tissue levels of adenosine are known to increase during hypoxia and are presumed to contribute to reactive hyperemia and hypoxia-induced vasodilatation. 1 While the vasodilating effects of adenosine in the cerebral, coronary, splanchnic, and renal circulations have been extensively studied, relatively few studies have assessed the effects of adenosine on the pulmonary vasculature. Adenosine has a very short half-life in blood due to rapid cellular uptake. We therefore hypothesized that if infused intravenously, adenosine would produce preferential pulmonary vasodilatation with significant inactivation by uptake before reaching the systemic circulation. The present study was designed to test this hypothesis.
Adenosine Produces Pulmonary Vasoconstriction in Sheep
Evidence for Thromboxane A 2 /Prostaglandin Endoperoxide-Receptor Activation Italo Biaggioni, Landon S. King, Nigar Enayat, David Robertson, and John H. Newman
Adenosine, an intermediate product in the metabolism of ATP, is thought to produce vasodilatation in all vascular beds with the exception of the kidney. Due to its theoretical potential as a pulmonary vasodilator, we studied the hemodynamic effects of adenosine in the pulmonary vasculature of chronically instrumented awake sheep. Adenosine produced significant pulmonary vasoconstriction instead of the expected vasodilatation. Bolus injections of adenosine into the superior vena cava produced a dose-dependent increase in pulmonary artery pressure that was entirely due to an increase in vascular resistance, since cardiac output decreased slightly. This effect is produced via activation of specific cell surface adenosine receptors, since it was blocked by the adenosine-receptor antagonists theophylline and dipropylsulfophenylxanthine. The cell type involved in adenosine-induced pulmonary vasoconstriction appears to be located within the lung, since vasoconstriction was blunted when adenosine was infused into the left atrium, distal to the lung. However, adenosine does not directly vasoconstrict the pulmonary vasculature, because its effect could be completely abolished by cyclooxygenase inhibition with either indomethacin or ibuprofen and by a thromboxane A 2 /prostaglandin endoperoxide-receptor antagonist (SQ 29,548). Adenosineinduced vasoconstriction was also greatly reduced after inhibition of thromboxane synthesis. Thus, adenosine produced pulmonary vasoconstriction through generation of a thromboxane/ endoperoxide product. Whether endogenous adenosine is involved in the generation of pulmonary vasoconstriction seen in pathophysiological states remains to be determined. To our knowledge, this is the first clear evidence for adenosine-induced vasoconstriction outside the kidney and for an interaction between adenosine and eicosanoid mechanisms. (Circulation Research 1989; 65:1516 -1525 A denosine is a vasodilator in virtually all vascular beds with the exception of the kidney. A product of ATP metabolism, adenosine has been postulated to be an endogenous modulator of blood flow. Tissue levels of adenosine are known to increase during hypoxia and are presumed to contribute to reactive hyperemia and hypoxia-induced vasodilatation. 1 While the vasodilating effects of adenosine in the cerebral, coronary, splanchnic, and renal circulations have been extensively studied, relatively few studies have assessed the effects of adenosine on the pulmonary vasculature. Adenosine has a very short half-life in blood due to rapid cellular uptake. We therefore hypothesized that if infused intravenously, adenosine would produce preferential pulmonary vasodilatation with significant inactivation by uptake before reaching the systemic circulation. The present study was designed to test this hypothesis.
We determined the hemodynamic effects of adenosine in the pulmonary vascular bed of chronically instrumented awake sheep. This animal model was chosen because its pulmonary circulation has been extensively studied. It was important for us to avoid the effects of anesthesia because the hemodynamic effects of adenosine differ in the conscious and anesthetized state in humans 2 and animals. 3 Our results show that adenosine produces significant pulmonary vasoconstriction instead of the expected vasodilatation. This effect is mediated through adenosine receptors located within the lung. However, it is not due to a direct vasoconstriction elicited by adenosine. Rather, it is mediated through adenosineinduced generation of a prostanoid product acting on thromboxane (TX) A 2 /prostaglandin endoperoxide receptors.
Materials and Methods Preparation
We studied a total of 15 adult sheep. Silastic catheters were inserted directly into the main pulmonary artery and left atrium through a left thoracotomy under pentobarbital induction and halothane anesthesia. These catheters were used to monitor pulmonary artery and left atrial pressures. An ultrasonic flow probe (Transonic Systems, Ithaca, New York) was placed around the pulmonary artery in nine of these sheep to monitor cardiac output continuously. A catheter for monitoring systemic blood pressure was also inserted into the thoracic aorta through cervical vessels. Catheters were exteriorized and sutured to the skin and flushed periodically with heparinized saline and chloramphenicol. On a different occasion, a thermal dilution 7F Swan-Ganz catheter (Cordis Laboratories, Miami, Florida) was passed into the pulmonary artery through an introducer placed in a jugular vein during surgery, for drug administration into the superior vena cava (proximal port) and pulmonary artery (distal port) and for cardiac output measurement. The animals were allowed to recover for at least 5 days before investigation.
Measurements
Sheep were studied unanesthetized and standing quietly in cages throughout each experiment. Mean pulmonary artery pressure, mean left atrial pressure, and aortic pressure were continuously monitored through the previously implanted catheters connected to pressure transducers (model 1208C, Hewlett-Packard, Palo Alto, California) and recorded on a Hewlett-Packard physiograph (model 7758A). Cardiac output was continuously monitored with an ultrasonic flow system (ultrasonic blood flowmeter, model T-101, Transonic Systems). The calibration and linearity of this system were assessed in vivo by comparing the cardiac output obtained by this system with that obtained by thermal dilution using the Swan-Ganz catheter and a cardiac output computer (model 9520A, Edwards Laboratories, Santa Ana, California) during graded infusions of isoproterenol. Pulmonary vascular resistance was calculated by subtracting mean left atrial pressure from mean pulmonary artery pressure and dividing by cardiac output. Total systemic resistance was calculated by dividing mean aortic pressure by cardiac output.
Experimental Protocols
To assess the hemodynamic effects of adenosine on the pulmonary circulation, adenosine was infused either as a continuous infusion or as rapid bolus injections into the superior vena cava via the proximal port of the Swan-Ganz catheter. Due to interindividual variability of the responses to adenosine (see "Results"), in subsequent studies adenosine doses were standardized to produce comparable increases in mean pulmonary artery pressure (approximately 10, 20, and 30 cm H 2 O). Adenosine was infused as rapid bolus injections at 30-minute intervals into the superior vena cava (through the proximal port of the Swan-Ganz catheter) or into the left atrium (through the left atrial catheter). At the beginning of each study day, increasing doses of adenosine were given until increments in pulmo- ). If acute changes in hemodynamic parameters were observed with these drugs, we waited until they returned to baseline levels. The predetermined doses of adenosine were then repeated in random order, and the results were compared with those previously observed in the same animal. The order of these interventions was randomly assigned, and they were carried out on separate days. We waited at least 2 days after the sheep received either indomethacin or ibuprofen before another intervention was assessed.
Blood samples for TXB 2 and 6-ketoprostaglandin F l a measurements were drawn in five sheep through the left atrial and pulmonary artery catheters. Samples were drawn simultaneously before and after bolus injection of either saline or adenosine, at the expected peak increase in pulmonary artery pressure.
Analytical Procedures
Plasma theophylline concentration was determined by high-performance liquid chromatography as previously described. 4 Briefly, 1 fig /3 -hydroxyethyltheophylline was added to 100 /xl plasma, and this solution was loaded onto an activated (2 ml methanol followed by 2 ml Millipore water) C 18 column (200-^,1 bed volume, Bond elute; Analytichem International, Harbor City, California). The column was then washed with 2 ml water, and methylxanthines were eluted with 600 fil acetone.
The eluent was evaporated under nitrogen, reconstituted in 100 fil mobile phase (2% acetic acid and 6% acetonitrile), and 5-10 pi were injected into a high-performance liquid chromatography system consisting of a pump (model M45, Waters Associated, Milford, Massachusetts) set at a delivery rate of 1.5 ml/min, injector (Rheodyne, Cotati, California), C 18 reverse phase column (Biophase OD5, BU Analytical Systems, West Lafayette, Indiana), and an ultraviolet detector (model 160, Beckman Instruments) set at a wave length of 280 nm. The peak height ratios of theophylline to /J-hydroxyethyltheophylline of the samples were compared with those obtained with a standard curve prepared in methylxanthine-free plasma.
Samples for eicosanoid measurements were collected over EDTA and analyzed by enzyme-linked immunoadsorbent assay as previously described. 5 Antibodies, enzymatic tracers, and specific eicosanoid antisera were obtained from AIA Reagents, Aurora, Colorado. Microtitration plates were coated with mouse monoclonal anti-rabbit immunoglobulin E. Enzyme tracer (TXB 2 covalently linked to purified acetylcholinesterase) was added to each sample well. Known standards or samples were incubated for 16 hours after addition of specific rabbit TXB 2 . Incubation was stopped with washings with 10 mM phosphate buffer. Wells were then filled with Ellman's reagent (acetylthiocholine iodide and 5-5"-dithiobis'-2-nitrobenzoic acid), and product was monitored at 414 nm by an automatic plate recorder (Tilestek Multiskan MC, Flow Laboratories). Nonspecific binding was determined by replacing specific antisera with assay buffer. The ratio of bound over nonspecific binding of the sample was compared with a standard curve processed simultaneously, to calculate picograms of TXB 2 per well, using a nonlinear curve fitting program. Cross reactivities of the TXB 2 antisera were as follows: TXB, 17%, 11-dehydro TXB 2 0.7%, prostaglandin D 2 0.2%, prostaglandin Ej 0.2%, and 6-ketoprostaglandin F lQ <0.1%.
Drugs
Adenosine was diluted in saline at concentrations of 1 or 5 mg/ml so that total volume injected was less than 3 ml. Theophylline and OKY-046 were diluted in saline. Indomethacin was diluted in 0.1 M sodium carbonate. SQ-29,548 was diluted in saline after conversion to its salt form with trizma base. Adenosine, theophylline, and indomethacin were purchased from Sigma Chemical, St. Louis, Missouri. Ibuprofen, OKY-046, and SQ-29,548 were generous gifts from The Upjohn Company, Kalamazoo, Michigan; Kissee Pharmaceutical, Matsumoto, Japan; and E.R. Squibb and Sons, Princeton, New Jersey, respectively. DPSPX was synthetized by hydrogenation of 1,3dipropyl-5-nitro-6-aminouracilin methanol, using platinum oxide as a catalyst, as previously described by Daly et al. 6 After hydrogenation was completed, the platinum oxide was removed by rapid filtration and the methanol by evaporation. The residue was suspended in water, and p-sulfobenzoic acid and l-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride were added. After stirring for 1 hour at room temperature, the mixture was concentrated on a rotary evaporator. Impurities were washed with diethylether. Excess ether was removed by evaporation. The resulting l,3-dipropyl-6-amino-5-(/7-sulfobenzamido) uracil was heated in 10% sodium hydroxide. The final solution was cooled in an ice bath and titrated to pH 4-5 with concentrated hydrochloric acid. The solid formed was collected by filtration and recrystallized from 95% ethanol. The purity of the compound was determined by high-performance liquid chromatography using a mobile phase consisting of 2% acetic acid and 13% acetonitrile at a flow rate of 1.5 ml/min. A reverse phase C 18 column was used, and ultraviolet absorbance was monitored at 310 and 254 nm. Injection of the synthetized DPSPX gave only one peak, which eluted at the same retention time as a commercially acquired standard (Research Biochemicals, Natick, Massachusetts). Peak heights obtained after injection of equal amounts of synthetized and commercial DPSPX were identical.
Statistical Analysis
Results are presented as mean±SD. Statistical analysis was performed using the CLINFO system of the VanderbUt Clinical Research Center and the NCSS statistical package (NCSS, Kaysville, Utah). Linear regression and / tests were used when appropriate. Multiple comparisons were done by two factor analysis of variance with replication 7 with one independent factor being adenosine dose (fixed, three levels) and the other independent factor being the different treatments (pretheophylline and posttheophylline, indomethacin, ibuprofen, etc., fixed and two levels). The dependent variables were the change in hemodynamic values induced by adenosine. Criteria for significance was/?<0.05.
Results
Continuous infusion of adenosine into the superior vena cava produced an initial increase in pulmonary artery pressure followed by rapid tachyphylaxis. As shown in Figure 1A , mean pulmonary artery pressure increased almost twofold within 30 seconds of adenosine infusion. After this initial increase, however, a gradual reduction in pulmonary artery pressure was observed despite sustained infusion, reaching a plateau still above baseline values approximately 30 seconds later. Mean systemic arterial blood pressure decreased slightly. Only after discontinuation of adenosine infusion did mean arterial pulmonary pressure return to preinfusion values, suggesting a mild degree of sustained pulmonary vasoconstriction.
Bolus injections of adenosine infused into the superior vena cava also produced significant increases in mean pulmonary arteiy pressure. This effect was seen within seconds of administration and was transient ( Figure IB) . A transient reduction in mean systemic blood pressure was also observed. On the contrary, equimolar doses of inosine, a major product of deamination of adenosine in blood, or of adenine, which lacks the ribose ring, produced no hemodynamic changes (data not shown), implying that the effects observed here were not the result of the generation of an active metabolite of adenosine.
There was great interindividual variability to the hemodynamic response to adenosine. As shown in Figure 2 , the dose of adenosine required to increase pulmonary artery pressure by 25 cm H 2 O varied 20-fold among the sheep studied. This difference could not be explained on the basis of weight nor gender. However, for individual sheep, the increase in pulmonary arterial pressure was dose-dependent, and the dose-response relation was extremely linear in the range of doses studied (Figure 2 ). Due to this variability, in subsequent experiments adenosine doses were individualized to produce increments in pulmonary artery pressure of approximately 10, 20, and 30 cm H 2 O. As shown in Table 1 , adenosine also produced a dose-dependent decrease in mean arterial blood pressure and an increase in heart rate. Left atrial pressure decreased significantly, and there was a small but significant decrease in cardiac output. Thus, the increase in pulmonary artery pressure was entirely due to an increase in pulmonary vascular resistance. On the other hand, the decrease in mean arterial blood pressure was due in part to a reduction in cardiac output and in part to systemic vasodilatation. The reduction in cardiac output could be due to venodilatation induced when adenosine was infused into the superior vena cava, producing an increase in venous capacitance and a decrease in venous return. To test the hypothesis, we compared the hemodynamic effects of adenosine infused either into the superior vena cava (through the proximal port of the Swan-Ganz catheter) or the pulmonary artery trunk (through the distal port of the Swan-Ganz catheter) in four sheep. In every case, hemodynamic responses were identical, implying that the reduction in cardiac output cannot be explained through this mechanism (data not shown). It is possible that the decline in cardiac output was secondary to the rise in pulmo- Data is expressed as raean±SD. Probability values arc obtained from analysis of variance for the differences between the three dose levels. nary vascular resistance. Adenosine has also been shown in vitro to have a negative inotropic action and to oppose the increase in left ventricular contractility produced by /?-adrenergic agonists. 8 Thus, there are several possible explanations for the decrease in cardiac output. All subsequent studies were done by injecting adenosine into the superior vena cava to ensure adequate mixing with blood in the heart chambers, before reaching the pulmonary vascular bed.
It seemed important to us to determine if the responses to adenosine were reproducible over time, especially since tachyphylaxis was observed during sustained infusions. Indeed, the hemodynamic effects of doses that increased pulmonary artery pressure by 10, 20, and 30 cm H 2 O were the same when repeated after 1 hour ( Table 2) . Adenosine produced also similar hemodynamic changes whether infused into the superior vena cava or the main pulmonary artery through the distal port of the Swan-Ganz catheter. On the contrary, when adenosine was infused into the left atrium, both the increase in pulmonary artery pressure as well as the decrease in mean arterial blood pressure were greatly blunted compared with the same doses infused into the superior vena cava (Figure 3 ). Taken together, these observations imply that adenosine-induced pulmonary vasoconstriction is generated within the lung, rather than from central or reflex mechanisms.
We also determined the effect of the following pharmacological probes on adenosine's actions: theophylline, an adenosine receptor antagonist; indomethacin and ibuprofen, two chemically unrelated cyclooxygenase inhibitors; OKY-046, a thrombox-ane synthase inhibitor 9 ; and SQ-29,548, a prostaglandin endoperoxide-receptor antagonist. 10 Only two of these drugs produced significant changes on baseline hemodynamic values. Ibuprofen reduced baseline heart rate from 109±16 to 97±16 beats/min (p< 0.025), and theophylline reduced baseline pulmonary artery pressure slightly from 17.3±3.2 to 15.4±3.1 cm H 2 O (p<0.005). Plasma levels of theophylline measured 1 hour after administration of 10 mg/kg i.v. were 12.6±2.8 /xg/ml. Pretreatment with each of these agents significantly blunted or completely abolished both the increase in pulmonary artery pressure and the decrease in mean arterial blood pressure (Figures 3  and 4 , Table 2 ), as well as the other hemodynamic changes induced by adenosine (not shown).
Theophylline at concentrations achieved clinically is an effective adenosine-receptor antagonist while having little effect on intracellular phosphodiesterase. 11 However, it is possible that theophylline may have other actions unrelated to adenosine-receptor antagonism. For this reason, the effect of a more potent and specific adenosinereceptor antagonism, DPSPX, was tested. The addition of the propyl and phenyl groups to the xanthine molecule confers greater potency as an adenosinereceptor antagonist. The addition of the sulfo group produces some reduction in potency but offers the advantage of making the compound water soluble and thus less able to enter the cell and act on intracellular phosphodiesterases. DPSPX had no effect on baseline hemodynamic measurements (n=4). However, DPSPX effectively antagonized the cardiovascular actions of adenosine (Table 2) , suggest- 
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Adenosine was infused as bolus injections into the superior vena cava at baseline (control) and 60 minutes later to determine the reproducibility of the effects of adenosine over time («=6), after administration of 3 mg/kg i.v. ibuprofen (n=5), and after administration of 10 mg/kg i.v. DPSPX (n=4). P PA , mean pulmonary artery pressure; MABP, mean arterial blood pressure.
Data are expressed as mean±SD. Probability values are those obtained from analysis of variance between groups (control vs. intervention).
ing that pulmonary vasoconstriction was indeed mediated through specific adenosine receptors.
Finally, we determined the effects of adenosine on plasma levels of TXB 2 in five sheep. Plasma concentrations of TXB2 from samples obtained from the pulmonary artery and the left atrium after bolus injections of saline were 88±36 and 86±33 pg/ml, respectively. The concentrations are similar to those found previously at rest in chronically instrumented awake sheep. 12 Samples obtained during peak increase in pulmonary artery pressure after bolus injections of adenosine revealed plasma concentrations of TXBj of 110±88 in the pulmonary artery and 278±121 pg/ml in the left atrium (Table 3) . Adenosine administration resulted in an increase in the transpulmonary gradient of TXBj. Plasma concentration in the left atrium of the prostacyclin metabolite 6-ketoprostaglandin F l o remained unchanged after adenosine administration (40± 10 pg/ml) as compared with saline (40±20 pg/ml).
Discussion
Our working hypothesis that adenosine would produce pulmonary vasodilatation in sheep proved to be wrong. Instead, adenosine produced pulmonary vasoconstriction, a new and unexpected finding. Heretofore, adenosinc was believed to produce vasodilatation in virtually all vascular beds with the exception of the kidney. The magnitude of the increase in pulmonary artery pressure observed after adenosine is similar to that reported after endotoxemia, 13 hypoxia, 14 -15 phorbol-induced granulocyte stimulation, 16 or complement activation. 17 This increase in pulmonary artery pressure was entirely due to an increase in pulmonary vascular resistance since cardiac output decreased slightly ( Table 1) . A decrease in mean arterial blood pressure was also observed when adenosine was infused into the superior vena cava. This effect cannot be attributed solely to peripheral vasodilatation produced by adenosine reaching the systemic circulation after crossing the lungs, because the decrease in systemic arterial pressure was blunted when adenosine was infused into the left atrium ( Figure 3A) .
Adenosine-induced pulmonary vasoconstriction was observed in all sheep studied and was reproducible over time. A tight linear dose-response relation was apparent for each animal studied (Figure 2) . Although large interindrvidual variability was observed. There was a 20-fold range of doses of adenosine required to produce the same increment in pulmonary artery pressure in all sheep. Of interest, contrasting adenosine cellular transport mechanisms can be identified within this species. Cells from some animals actively uptake adenosine by a nucleoside transporter system. This mechanism is functionally absent from cells of other sheep. 18 Once inside a cell, adenosine is rapidly metabolized and inactivated. Therefore, cellular uptake is probably the limiting factor that determines the concentration of adenosine available at specific cell surface receptors, its site of action. We can speculate then that animals with very active adenosine uptake mechanisms would require more drug to attain the same effect as animals with less active transport systems.
Our results also show that the hemodynamic effects of adenosine require the activation of specific cell surface adenosine receptors, since they are blocked by theophylline at plasma concentrations within the therapeutic range ( Figure 3B ) and by DPSPX, a more specific adenosine-receptor antagonist ( Table 2 ). The actions of adenosinc were greatly reduced when infused into the left atrium, distal to the lung ( Figure 3A) . We interpret these results as indicative that the cells responsible for adenosine actions are located within the lung and that adenosine-induced pulmonary vasoconstriction is not due to central nor reflex mechanisms. This is particularly important since adenosine-induced chemoreceptor activation observed in animals 19 and in humans 20 " 22 can cause secondary hemodynamic changes.
Adenosine receptors are present on vascular smooth muscle cells, and their activation has been extensively shown to produce vasodilatation. Adenosine also produces pulmonary vasodilatation in isolated ferret lungs previously vasoconstricted by hypoxia. 23 Therefore, it seems unlikely that the observed pulmonary vasoconstriction would be due to a direct action of adenosine on the pulmonary vasculature. We hypothesized then that the increase in pulmonary artery pressure was mediated through the generation of a pulmonary vasoconstrictor substance. In fact, two chemically unrelated cyclooxygenase inhibitors, indomethacin and ibuprofen, completely abolished the hemodynamic effects of adenosine ( Figure 4A and Table 2 ), implying that the pulmonary vasoconstriction was mediated through generation of a cyclooxygenase product.
To further determine the role of prostanoid mechanisms on adenosine actions, we used the TXA2/ prostaglandin endoperoxide-receptor antagonist SQ-29,458. 10 We used a dose previously shown to increase by almost 20-fold the dose of the thromboxane agonist U46619 required to raise pulmonary artery pressure by 20 cm H 2 O in sheep. 13 Blockade of TXA^prostaglandin endoperoxide receptors by SQ-29,458 completely abolished adenosine-induced increase in pulmonary artery pressure ( Figure 4B) . A simple interpretation of these findings is that thromboxane, a known pulmonary vasoconstrictor, was solely responsible for adenosine actions since SQ-29,458 appears to be a selective antagonist of the TXA^prostaglandin endoperoxide receptor. 10 -24 However, the contribution of other pulmonary vasoconstrictor prostanoids cannot be excluded, since we have recently found that in sheep, two chemically unrelated thromboxane/endoperoxide-receptor antagonists, AH-2388 and SQ-29,498, selectively antagonize the increase in pulmonary artery pressure, but not the increase in systemic blood pressure produced by prostaglandin D2. 25 Similar findings have been reported in guinea pig tracheal strips by Ogletree et al, 10 implying that the TXA2/ prostaglandin endoperoxide receptor in certain tissues is nonselective for several vasoconstrictor prostaglandins.
Finally, we used a thromboxane synthase inhibitor OKY-046 at doses previously shown by Kubo and Kobayashi 9 to completely abolish thromboxane generation induced by endotoxemia in sheep. Inhibition of thromboxane generation greatly reduced, but did not completely abolish, adenosine-induced increase in pulmonary artery pressure ( Figure 4Q . We interpret these results to indicate that the pulmonary vasoconstriction seen after adenosine is due at least partially to adenosine-induced TXA 2 generation. That adenosine actions were not completely abolished by OKY-046 can be explained by the fact that isolated inhibition of thromboxane synthesis creates shunting toward alternative metabolic pathways, with accumulation of endoperoxides and perhaps synthesis of other pulmonary vasoconstrictor prostaglandins. 13 That TXA 2 contributes to adenosine-induced pulmonary vasoconstriction is further supported by the observed increase in TXB2 in the left atrium, but not in the pulmonary artery, after bolus injections of adenosine. However, potential ex vivo generation of TXB 2 limits the interpretation of these measurements. 26 In conclusion, thromboxane appears to be a major mediator of the pulmonary vasoconstriction induced by adenosine, but the contribution of other vasoconstrictor cyclooxygenase products (e.g., an endoperoxide or prostaglandin D 2 ) cannot be excluded.
The cell type that generates the cyclooxygenase products responsible for the hemodynamic effects of adenosine appears to be located within the lung. However, it could be either a parenchymal or a circulating blood cell. Platelets are an important source of thromboxane in humans and many other animal species, but sheep platelets produce only 17% of the thromboxane generated by human platelets when stimulated with collagen. 17 Likewise, endotoxemia-induced release of thromboxane by the lung is not altered by platelet depletion in sheep. 27 Furthermore, adenosine prevents platelet activation. 28 Adenosine also prevents neutrophil activation. 29 Endothelial cells are known to modulate smooth muscle tone, are a weak source of TXA 2 , M and possess adenosine receptors. 31 However, adenosine receptor activation in endothelial cells, if anything, produces vasodilatation. 32 On the contrary, adenosine produces mast cell activation and degranulation, 33 " 35 and mast cells are sources of vasoconstrictor prostaglandins, particularly prostaglandin D 2 and thromboxane.s*- 35 The identification of the cell or tissue responsible for adenosineproduced pulmonary vasoconstriction awaits further study.
Whether the pulmonary response to adenosine observed in this study occurs in humans is unknown. Preliminary observations demonstrate that adenosine also produces pulmonary vasoconstriction in the closed-chest, spontaneously breathing cat 36 and contractions of guinea pig pulmonary artery spiral strips in vitro. 37 It has not been determined whether these actions also involve cyclooxygenase products. These reports suggest that adenosine-induced pulmonary vasoconstriction is seen in various animal species.
From our results, we obviously cannot draw conclusions on the role of endogenous adenosine; however, they Taise the possibility that endogenous adenosine is involved in the genesis of the pulmonary vasoconstriction seen in pathophysiological states.
In summary, adenosine produces pulmonary vasoconstriction instead of the expected vasodilatation in sheep. The effect is produced by the activation of a theophylline-sensitive adenosine receptor on a cell located within the lung. This activation leads to the generation of a cyclooxygenase product that mediates the pulmonary vasoconstriction observed via activation of TXA^prostaglandin endoperoxide receptor. The potential role of endogenous adenosine on the generation of pulmonary vasoconstriction seen in pathophysiological states remains to be determined. To our knowledge, this is the first clear evidence in vivo of adenosine-induced vasoconstriction in a vascular bed outside the kidney. That these effects are mediated through eicosanoid mechanisms is also a novel observation. Note added in proof: While this work was in press, a preliminary report has appeared showing that adenosine-induced pulmonary vasoconstriction in cats can be blocked by a cyclooxygenase inhibitor (Neely CF et al. FASEB J 1989; 3:8280 ), suggesting that the effects reported here are not circumscribed to the animal species studied. Furthermore, Dr. Neely has drawn to our attention that Drury and Szent-Gyorgy observed increments in pulmonary pressure when adenosine was administered in a dog heart-lung preparation. They interpreted this finding as secondary to an increase in flow rather than pulmonary vasoconstriction (JPhysiol 1929;68:213).
